# Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

> **NCT05587712** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 42 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Sotatercept

## Key facts

- **NCT ID:** NCT05587712
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-19
- **Primary completion:** 2028-09-21
- **Final completion:** 2028-09-21
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05587712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05587712, "Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05587712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*